Workflow
海通证券现金管理产品
icon
Search documents
湖北济川药业股份有限公司关于全资子公司利用闲置募集资金进行现金管理到期赎回并继续进行现金管理的进展公告
Core Viewpoint - The company is utilizing idle raised funds for cash management, with a total amount not exceeding 580 million RMB, ensuring the safety and liquidity of investments while maintaining the normal implementation of fundraising projects [2][9]. Summary by Sections Previous Cash Management - The company previously redeemed cash management products, recovering a total principal of 112 million RMB with respective earnings of 129,100 RMB, 292,600 RMB, and 616,400 RMB, and annualized returns of 2.17%, 1.20%, and 2.50% [4][3]. Current Cash Management Overview - The purpose of cash management is to enhance the efficiency of idle raised funds, with a current cash management amount of 20 million RMB [5][6]. - The source of funds for this cash management is from idle raised funds from a non-public offering in 2020 [7][8]. Cash Management Details - The company plans to invest 10 million RMB each in two structured deposits at Bohai Bank [9]. Approval Process - The cash management proposal was approved during the board and supervisory meetings held on April 25, 2025, and the annual shareholders' meeting on May 16, 2025 [9]. Financial Impact - As of June 30, 2025, the company's debt-to-asset ratio was 18.85%, indicating no significant debt while engaging in cash management [11]. - The cash management principal will be recorded as "trading financial assets" on the balance sheet, with earnings reflected in the profit statement as "investment income" [11]. Recent Cash Management Activities - The company has been actively managing raised funds over the past twelve months, indicating a strategic approach to utilizing idle resources [11].